Gonadotropin-releasing hormone (GnRH) antagonist plus recombinant luteinizing hormone vs. a standard GnRH agonist short protocol in patients at risk for poor ovarian response.
Various studies have compared the efficacy of GnRH agonists (GnRH-a) and antagonists (GnRH-ant) for controlled ovarian stimulation (COS) in women undergoing IVF. Nevertheless, few data are available about the use of GnRH-ant in poor responders. Here, a flexible protocol providing a gradual increase in the dose of GnRH-ant in association with recombinant LH (rec-LH) administration is compared with the standard GnRH-a flare-up protocol in 133 women at risk for poor ovarian response. The mean number of metaphase 2 oocytes (primary end point) was significantly higher in the antagonist group (5.73 +/- 3.57 vs. 4.64 +/- 2.23, respectively; P<.05).
De Placido
Giuseppe
G
Dipartimento Universitario di Scienze Ostetriche Ginecologiche e Medicina della Riproduzione, Università degli Studi di Napoli Federico II, Naples, Italy.
Mollo
Antonio
A
Clarizia
Roberto
R
Strina
Ida
I
Conforti
Salvatore
S
Alviggi
Carlo
C
D000328:Adult; D004359:Drug Therapy, Combination; D005260:Female; D005307:Fertilization in Vitro; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists* / Q000037:antagonists & inhibitors*; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy* / Q000453:epidemiology; D007986:Luteinizing Hormone / Q000008:administration & dosage*; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D018873:Pregnancy Rate; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000008:administration & dosage; D012307:Risk Factors
D011994:Recombinant Proteins; D007987:Gonadotropin-Releasing Hormone; D007986:Luteinizing Hormone